Call for Changes in Clinical Trial Reporting of Older Patients With Cancer [Correspondence] opens in pdf file

"In studies in which older patients make up a significant proportion
(>15%) of the study population, an analysis of the possible
interaction between outcome, toxicity, and age should be provided in
detail according to specific patient characteristics (comorbidity, function,
and so on). Toxicity should include a reporting of grade 2 toxicities,
when appropriate, given that grade 2 toxicity can be significant in
a patient age 75 years."


"In sum, clinical trials currently fail to address the issues involved
in treating an aging patient with cancer. Designers of clinical cancer
trials must begin to incorporate statistical analyses related to aging, so
that clinicians can optimize their treatment of the older patient
with cancer."